PatternsRadar
Sign in

SUNPHARMASun Pharmaceutical Industries Limited

NSEF&O
Full chart
1,804.10INR+24.40 (+1.37%)Close · 6 Oct 2026
31 Jul 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹4.33L CrMarket cap
35.7P/E (TTM)
59.9%Delivery

Filings & corporate actions

85 results filed
CSV
Next results · Q2 FY27
Expected 28 Oct 2026 – 5 Nov 2026
Estimate: filed 28–36 days after quarter end, last 5 times
Dividend
₹5.00 per share · last 7 Jul 2026
2026
  • 31 JulresultsResults · Q1 FY27 · consolidated and standalone-1.4%NSE
  • 17 JulshareholdingShareholding · 30 Jun 2026-0.9%NSE
  • 7 JuldividendDividend · ₹5.00 per share-0.5%
  • 22 MayresultsResults · Q4 FY26 · consolidated and standalone-0.2%NSE
  • 17 AprshareholdingShareholding · 31 Mar 2026-1.0%NSE
  • 5 FebdividendDividend · ₹11.00 per share-0.1%
  • 31 JanresultsResults · Q3 FY26 · consolidated and standalone+0.9%NSE
  • 15 JanshareholdingShareholding · 31 Dec 2025-1.9%NSE

Reaction to results · all yearsrose on day 0 in 39 of 76 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2731 Jul 2026-1.4%-2.3%-0.3%1.6×
Q4 FY2622 May 2026-0.2%-3.0%+1.3%0.6×
Q3 FY2631 Jan 2026+0.9%+6.3%+8.9%0.9×
Q2 FY265 Nov 2025-0.2%+2.8%+7.6%1.9×
Q1 FY2631 Jul 2025-4.5%-7.0%-8.3%4.9×
Q4 FY2522 May 2025-2.0%-2.4%-3.1%2.9×
Q3 FY2531 Jan 2025-0.1%+0.3%-9.1%0.8×
Q2 FY2528 Oct 2024-1.6%-5.2%-8.9%1.3×
Q1 FY251 Aug 2024+1.0%+1.2%+5.9%1.3×
Q4 FY2422 May 2024-2.9%-5.2%-4.7%5.7×
Q3 FY2431 Jan 2024-0.7%+5.7%+11.2%1.1×
Q2 FY241 Nov 2023+1.5%+5.4%+10.3%1.9×
Q1 FY243 Aug 2023-0.2%-0.8%-2.8%1.2×
Q4 FY2326 May 2023-0.1%+4.0%+2.6%2.1×
Q3 FY2331 Jan 2023-1.9%-2.1%-7.3%2.2×
Q2 FY231 Nov 2022+1.5%-2.5%+1.0%2.1×
Q1 FY2329 Jul 2022-2.6%-3.5%-7.6%1.5×
Q4 FY2231 May 2022-3.1%-4.5%-6.7%7.5×
Q3 FY2231 Jan 2022+6.9%+7.1%-1.6%3.3×
Q2 FY222 Nov 2021-3.4%-2.5%-7.8%2.7×
Q1 FY2230 Jul 2021+0.1%+1.9%+2.6%3.8×
Q4 FY2128 May 2021-4.3%-3.7%-3.9%3.5×
Q3 FY2129 Jan 2021+0.7%+8.3%+3.1%1.6×
Q2 FY214 Nov 2020+3.9%+4.2%+17.2%5.9×
Q1 FY211 Aug 2020-2.3%+2.3%-2.2%2.3×
Q4 FY2027 May 2020+1.8%+9.7%+8.2%1.1×
Q3 FY206 Feb 20200.0%-2.8%-8.7%1.9×
Q2 FY208 Nov 2019-4.2%-3.6%-3.1%2.2×
Q1 FY2013 Aug 2019-5.0%-5.6%-2.8%2.6×
Q4 FY1929 May 2019+2.7%-2.1%-2.4%3.7×
Q3 FY1920 Feb 2019+1.7%+5.4%+10.0%0.5×
Q2 FY1922 Nov 2018-2.9%-13.4%-19.3%0.9×
Q1 FY1931 Aug 2018+2.0%+3.8%-3.0%1.6×
Q4 FY1819 Jun 2018+0.7%+3.0%-1.8%0.5×
Q3 FY1822 Feb 2018+5.2%+1.3%-7.1%4.0×
Q2 FY1821 Nov 2017+4.0%+5.0%+2.0%1.6×
Q1 FY1821 Aug 2017+2.1%+5.1%+9.8%0.7×
Q4 FY1718 Jun 2017-0.8%+2.8%+9.3%0.4×
Q3 FY1717 Feb 2017+4.0%+3.9%+7.5%1.7×
Q2 FY1710 Nov 2016+3.3%+3.6%+1.5%3.0×
Q1 FY1721 Sept 2016+1.0%-5.5%-4.1%0.7×
Q4 FY1631 May 2016-6.1%-9.0%-5.8%5.9×
Q3 FY1613 Feb 2016+0.3%+4.1%-0.5%1.2×
Q2 FY167 Nov 2015-5.8%-6.2%-5.5%3.6×
Q1 FY1611 Aug 2015+2.9%+10.2%-0.3%1.2×
Q4 FY154 Jun 2015-1.3%-2.7%+3.4%1.4×
Q3 FY1518 Feb 2015-0.1%-5.7%+14.2%0.5×
Q2 FY1519 Nov 2014-1.9%-3.1%-6.4%1.7×
Q1 FY1518 Aug 2014+0.2%+4.7%-2.0%0.7×
Q4 FY1429 May 2014+4.1%+2.2%+12.7%4.3×
Q3 FY1419 Feb 2014-0.6%+3.4%-6.2%0.6×
Q2 FY1421 Nov 2013-1.1%-1.6%-0.4%1.5×
Q1 FY1414 Aug 2013+0.6%-8.3%+3.0%1.0×
Q4 FY136 Jun 2013-1.8%-8.4%-0.6%0.6×
Q3 FY138 Feb 2013+0.4%+5.6%+11.7%1.0×
Q2 FY138 Nov 2012-0.3%-2.3%+2.7%0.7×
Q1 FY1310 Aug 2012+1.0%-1.7%+1.4%1.1×
Q4 FY121 Jun 2012+0.4%+2.9%+12.1%0.9×
Q3 FY1213 Feb 2012+2.2%+0.3%+7.8%2.3×
Q2 FY1214 Nov 2011+1.3%-1.1%+1.6%1.3×
Q1 FY1228 Jul 2011-0.2%-3.9%-10.3%1.1×
Q4 FY1130 May 2011+4.4%+7.4%+10.5%2.6×
Q3 FY1131 Jan 2011-1.8%-8.6%-5.6%1.5×
Q2 FY1130 Oct 2010+3.8%+8.8%+6.1%1.5×
Q1 FY1128 Jul 2010+1.8%+0.2%+0.7%2.7×
Q3 FY1029 Jan 2010+2.3%+0.7%+5.3%1.5×
Q2 FY1028 Oct 2009+0.5%+1.1%+7.0%1.4×
Q1 FY1029 Jul 2009-5.4%-5.9%-3.9%2.7×
Q3 FY0930 Jan 2009-2.6%+1.6%-9.6%1.1×
Q2 FY0925 Oct 2008-8.0%-17.5%-13.7%1.1×
Q1 FY0928 Jul 2008+1.1%+4.1%+6.1%0.8×
Q4 FY0830 May 2008+3.1%+3.8%-0.1%1.5×
Q3 FY0830 Jan 2008+8.7%+3.2%+13.0%2.8×
Q2 FY0825 Oct 2007+2.5%+5.5%+8.4%0.6×
Q1 FY0823 Jul 2007+0.8%-5.5%-3.6%2.2×
Q4 FY0718 May 2007-0.3%+4.8%+4.0%0.3×
Average+0.1%-0.0%+0.7%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+10.5%
Profit YoY+26.5%
Interest cost YoY—
Revenue QoQ+4.7%
Profit QoQ+7.1%
CAGR2Y3Y4Y5Y6Y7Y
Revenue——————
Profit——————

Key data

CSV
Open1,775.00
Day range1,768.00 – 1,804.10
52-week range1,580.00 – 2,046.90
From 52w high-11.9%
RSI (14)39.7
ATR (14)32.17
Volume14.78L
Avg volume (20D)16.27L
Rel volume0.91×
Volatility (1Y)19.5%
Turnover₹266.7Cr
SMA 50 / 2001,900.07 / 1,807.61

Delivery percentage

Latest · 6 Oct 202659.9%
20-day avg64.5%
1-year avg64.1%
Percentile (own history)62nd
Range8.1–83.7%
Sessions1,731

Over the last 20 sessions SUNPHARMA settled 64.5% of its traded quantity, which is unusually high for an NSE equity. That is in line with its own one-year average of 64.1%. The latest session ranks higher than 62% of the 1,731 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSWOCKPHARMADRREDDYMOREPENLABZYDUSLIFE

Performance returns

CSV
1D1W1M3M6M1Y
Price+1.37%-1.84%-5.84%-5.22%+6.52%+13.70%

Valuation

CSV
Market cap₹4.33L Cr
P/E (TTM)35.7
EPS (TTM)50.50
Shares outstanding239.93Cr
Listed8 Feb 1995

Ownership

CSV
Promoter—
Promoter Δ QoQ—
Public—
FII—
DII—
Pledged—

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)14,478.315,520.514,611.815,299.9
YoY chg——+12.8%+10.5%
Net profit (₹ Cr)3,125.03,381.22,709.72,901.2
YoY chg——+25.8%+26.5%
Net margin21.6%21.8%18.5%19.0%
EPS13.0014.0011.3012.10

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 54.48% · public 45.52%
30 Sept 2021: promoter 54.48%31 Dec 2021: promoter 54.48%31 Mar 2022: promoter 54.48%30 Jun 2022: promoter 54.48%30 Sept 2022: promoter 54.48%31 Dec 2022: promoter 54.48%31 Mar 2023: promoter 54.48%30 Jun 2023: promoter 54.48%30 Sept 2023: promoter 54.48%31 Dec 2023: promoter 54.48%31 Mar 2024: promoter 54.48%30 Jun 2024: promoter 54.48%30 Sept 2024: promoter 54.48%31 Dec 2024: promoter 54.48%31 Mar 2025: promoter 54.48%30 Jun 2025: promoter 54.48%30 Sept 2025: promoter 54.48%31 Dec 2025: promoter 54.48%31 Mar 2026: promoter 54.48%30 Jun 2026: promoter 54.48%
2021-092026-06
  • Promoter
  • Public and others
Promoter
54.48%
Public
45.52%
Promoter change
0.00 pp
Filed
17 Jul 2026
FII
14.53%
DII
22.18%
Promoter pledged
1.65%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q1 FY24Q2 FY24Q3 FY24Q4 FY24AQ2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations11,940.812,192.412,380.711,982.913,291.413,675.512,958.813,851.414,478.315,520.514,611.815,299.9
Other income204.4293.6250.2605.9354.0465.6612.9464.5469.9578.8458.5723.6
Total income12,145.312,486.012,630.912,588.813,645.414,141.113,571.714,315.914,948.216,099.415,070.316,023.5
Total expenses9,341.39,695.19,560.79,671.710,047.510,348.59,955.710,325.110,780.611,382.711,519.011,720.6
└ Finance costs80.949.334.773.669.251.549.174.899.978.485.999.7
└ Depreciation651.3632.8622.1650.4625.9630.6663.8700.6729.5732.3775.5738.7
Profit before tax2,481.12,790.93,000.42,815.53,597.93,476.43,254.43,172.84,167.64,227.23,551.34,098.8
Tax expense468.1390.1432.3148.9567.2558.91,093.7870.21,030.5826.1827.61,188.0
Net profit2,005.72,385.12,560.52,658.73,037.32,913.02,153.92,292.93,125.03,381.22,709.72,901.2
EPS8.409.9010.5011.1012.7012.109.009.5013.0014.0011.3012.10
Net margin16.80%19.56%20.68%22.19%22.85%21.30%16.62%16.55%21.58%21.79%18.54%18.96%
PBT margin20.78%22.89%24.23%23.50%27.07%25.42%25.11%22.91%28.79%27.24%24.30%26.79%
Tax rate18.87%13.98%14.41%5.29%15.77%16.08%33.61%27.43%24.73%19.54%23.30%28.98%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 31 Jul 2026.

SUNPHARMA at a glance

  • SUNPHARMA closed at ₹1,804.1 on 6 Oct 2026, +1.37% on the day, +13.7% over one year, 11.9% below its 52-week high of ₹2,046.9.
  • Delivery was 59.9% of traded quantity on 6 Oct 2026, the 62nd percentile of its own 1,731 sessions with a reading (20-session average 64.5%, 1-year average 64.1%).
  • Market capitalisation is ₹4.33 lakh crore at a trailing P/E of 35.7 (trailing EPS ₹50.5).
  • Q1 FY27 results (consolidated, filed 31 Jul 2026): revenue ₹15,300 crore (+10.5% year on year), net profit ₹2,901 crore (+26.5%); the price moved -1.4% on the first session after.
  • Promoters held 54.48% at 30 Jun 2026, unchanged on the previous filing, with 1.65% of promoter shares pledged.
  • Q2 FY27 results are expected between 28 Oct 2026 and 5 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE044A01036
SeriesEQ
Listed8 Feb 1995
History from9 Feb 1995
Sessions7,820
Turnover rank#81

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE